Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903109 · ClinicalTrials.gov registry record · Early Phase 1
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
A Early Phase 1 study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
NCT01903109: Completed Early Phase 1 study, sponsored by Roxane Laboratories.
NCT01903109 is a Early Phase 1 study that has completed, run by Roxane Laboratories. The registered enrollment target is 27 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01903109, a Early Phase 1 study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
Interventions
- DRUG Cevimeline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-02 |
| Phase | Early Phase 1 |
What the finished NCT01903109 record still lists
NCT01903109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 1 intervention - of which Cevimeline is the first listed.
NCT01903109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01903109 about?
NCT01903109 is a clinical study titled "Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
What is the current status of trial NCT01903109?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2009-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT01903109?
The interventions under investigation include: Cevimeline (DRUG).
Who is sponsoring clinical trial NCT01903109?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01903109's enrollment target sits among peer trials
27 963rd of 2000 higher than 1,024 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia